Veliparib - Abbvie
Alternative Names: ABT-888; NSC-737664Latest Information Update: 24 Jun 2024
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie
- Class Amides; Antineoplastics; Benzimidazoles; Pyrrolidines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fallopian tube cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Phase II/III Glioblastoma
- Phase II Brain metastases; Breast cancer; Colorectal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours; Testicular cancer
- Phase I/II Glioma; Head and neck cancer; Small cell lung cancer
- No development reported Lymphoma; Multiple myeloma; Prostate cancer
- Discontinued Liver cancer
Most Recent Events
- 05 Apr 2024 Efficacy data from the phase II I-SPY trial in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 25 Jan 2024 AbbVie completes a phase III trial in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA, Austria, Argentina, Australia, Belgium, Finland, Portugal, Hungary, Latvia, Spain, Puerto Rico, Ukraine, Turkey, Taiwan, South Africa, Singapore, Russia, Romania, Poland, Norway, the Netherlands, Mexico, Lithuania, South Korea, France, Israel, Germany, Estonia, Denmark, Czech Republic, Colombia, Chile, Canada, Belarus, the UK, Sweden and Italy(PO) (NCT02163694) (EudraCT2014-000345-70)
- 30 Oct 2023 Abbvie terminates a phase III VELIA trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Combination therapy, First-line therapy, Late-stage disease) in USA, Australia, Brazil, Denmark, Israel, Japan, South korea, New Zealand, Poland, Spain and United Kingdom (PO) due to business decision and not due to patient safety (NCT02470585)